Tagged with OP

Opinion Becton Dickinson’s Fiona Garín looks at the rise of Healthcare-Acquired Infections (HAIs) in Europe and how an industry-wide culture of safety needs to be developed to counter this growing threat.   Healthcare systems in Europe are becoming more complex in their quest to drive affordability, quality of care and patient…

Opinion The AAM’s Chip Davis looks back on 35 years of healthcare system savings from generic pharmaceuticals in the US, and the peril the generics industry faces from the Lower Health Care Costs Act.   A key provision of our generic pharmaceutical architecture is in jeopardy. The “180-day exclusivity” is the…

USA Carla Smith looks at the three vital components behind successful strategic alliances in US healthcare:disruption,  data-driven demands and convenient care delivery.   Throughout my career, to bring positive and lasting change to the health sector, I’ve brokered more collaborative efforts than I can count. Strategic alliances between health leaders, nonprofit…

Korea Multinational pharma company managers working abroad must adapt to new cultures and develop a deep understanding of local markets. Korea is no different; here three foreign country managers give their first impressions and insights into the Korean pharma market.   Nic Horridge, Roche   As a newcomer in the land…

Opinion Eurasia Group’s Aditya Bhattacharji tackles three more key geopolitical issues that global pharma needs to be cognizant of: the world’s leading drug regulators becoming increasingly strident and active beyond national borders; the impact that greater awareness and work on climate change could have on the industry; and the risks surrounding…

Asia-Pacific Ai Hua Ong, Asia-Pacific company group chairman of Janssen, the Pharmaceutical Companies of Johnson & Johnson, looks back at the tremendous progress the pharmaceutical industry has made in the Asia-Pacific region over the last ten years and highlights how the industry needs to adapt to meet emergent challenges.   By…

USA Boston University School of Law’s Kevin Outterson* looks at how cost-saving measures are contributing to the rise of drug-resistant “superbugs” in the US and the steps that need to be taken to remedy the situation.   Globally, 700,000 people lose their lives to drug-resistant infections each year In November 2019,…

Opinion Monica Weldon, CEO and president of Bridge the Gap – SYNGAP Education and Research Foundation, shares her recent experience at the US Drug Law and Regulation course in Washington, DC and expands on the role that patient associations can play in the drug development process.   In today’s environment of…

Puerto Rico Rolando Torres, executive vice president of global manufacturing for CooperVision, explains why Puerto Rico is a force to be reckoned with in medical device and pharmaceutical manufacturing. Moreover, he provides a general overview of their manufacturing operations and their large-scale efforts to make sustainable practices the new global standard.  …

Opinion Michael Jewell, partner and head of healthcare & life sciences at Cavendish Corporate Finance looks back at the key trends across pharma industry funding in 2019 and gives his perspective on how 2020 will look.   As we approach the end of 2019, it’s a good time to look back…

Opinion Steve Brooks, Advisor to the AMR Industry Alliance, outlines the threat that antimicrobial resistance (AMR) poses to global health,  how antibiotic manufacturing may be a contributing factor to AMR  and how responsible manufacturing processes can minimize any such contribution.   The causes of antimicrobial resistance are numerous, from over prescribing to…

Global The IFPMA’s Greg Perry shares some of the key findings from a panel discussion on access to healthcare products at the 2019 World Health Summit in Berlin and the vital importance of cross-sector partnerships in driving access to medicines and vaccines across the globe.   In October I had the…